Allogeneic Stem Cell Transplant Recipient

1

Review clinical trials related to Allogeneic Stem Cell Transplant Recipient. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

The Flu-TBI 800 trial is a prospective, single-arm, multicenter, interventional phase 2 study to evaluate whether fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy) (experimental regimen) improves the 1-year survival of allogeneic stem cell transplant recipients.

Participants needed: 209
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Hackensack Meridian HealthUpdated: Mar 23, 2026Locations: 3
Eligibility criteria

Patients ages 18-65 years. [+17]

Hematopoietic cell transplantation comorbidity index above 3. [+5]